TY - JOUR
T1 - Tardive dyskinesia and atypical antipsychotic drugs
AU - Casey, Daniel E.
N1 - Funding Information:
Supported in part by the Mental Illness Research, Education, and Clinical Center (MIRECC), VISN 20, the VA Medical Research Program, NIH grant MH36657, and CORE grant RP00163.
PY - 1999/3/1
Y1 - 1999/3/1
N2 - Typical antipsychotic agents produce central nervous system effects, especially extrapyramidal symptoms (EPS) and tardive dyskinesia (TD). Nearly every patient who receives neuroleptic therapy has one or more identifiable risk factors for TD, among the most significant of which are older age, female gender, presence of EPS, diabetes mellitus, affective disorders, and certain parameters of neuroleptic exposure (i.e. dose and duration of therapy). The typical course of TD is a gradual onset after several years of drug therapy, followed by slow improvement or remission, but a large number of patients have persistent TD with irreversible symptoms. In the management of TD, the patient's mental status is of primary concern. Currently, no uniformly safe and effective therapies for TD exist, though a variety of therapeutic agents, including some of the atypical neuroleptics, have been reported to treat TD successfully in some patients. Because TD liability is so much lower with novel antipsychotic therapy, all patients who have TD or are at risk for TD, as well as EPS, should be considered candidates for switching to these new drugs.
AB - Typical antipsychotic agents produce central nervous system effects, especially extrapyramidal symptoms (EPS) and tardive dyskinesia (TD). Nearly every patient who receives neuroleptic therapy has one or more identifiable risk factors for TD, among the most significant of which are older age, female gender, presence of EPS, diabetes mellitus, affective disorders, and certain parameters of neuroleptic exposure (i.e. dose and duration of therapy). The typical course of TD is a gradual onset after several years of drug therapy, followed by slow improvement or remission, but a large number of patients have persistent TD with irreversible symptoms. In the management of TD, the patient's mental status is of primary concern. Currently, no uniformly safe and effective therapies for TD exist, though a variety of therapeutic agents, including some of the atypical neuroleptics, have been reported to treat TD successfully in some patients. Because TD liability is so much lower with novel antipsychotic therapy, all patients who have TD or are at risk for TD, as well as EPS, should be considered candidates for switching to these new drugs.
KW - Atypical antipsychotics
KW - Clozapine
KW - Extrapyramidal symptoms
KW - Olanzapine
KW - Risperidone
KW - Tardive dyskinesia
UR - http://www.scopus.com/inward/record.url?scp=0033104913&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033104913&partnerID=8YFLogxK
U2 - 10.1016/S0920-9964(98)00160-1
DO - 10.1016/S0920-9964(98)00160-1
M3 - Article
C2 - 10190226
AN - SCOPUS:0033104913
SN - 0920-9964
VL - 35
SP - S61-S66
JO - Schizophrenia Research
JF - Schizophrenia Research
IS - SUPPL.
ER -